Interferon beta, Drugs Monitor

(08 Jan 2021) Interferon beta- associated with decrease in death risks

January 14, 2021

Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients https://doi.org/10.1016/j.intimp.2020.107329 We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units… Continue reading "(08 Jan 2021) Interferon beta- associated with decrease in death risks"

(16 Nov 2020) Interferon beta- nebulised interferon beta 1a helped in rapid recovery

November 21, 2020

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial https://doi.org/10.1016/S2213-2600(20)30511-7 This trial is registered with Clinicaltrialsregister.eu (2020-001023-14) and ClinicalTrials.gov (NCT04385095); the pilot trial of inpatients with COVID-19 is… Continue reading "(16 Nov 2020) Interferon beta- nebulised interferon beta 1a helped in rapid recovery"

(13 Nov 2020) Favipiravir, Interferon beta- no significant differences in clinical outcome in comparison to HCQ

November 20, 2020

Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia https://www.ijidonline.com/article/S1201-9712(20)32319-5/pdf A total of 89 patients underwent randomization with 49% (n = 44) assigned to favipiravir… Continue reading "(13 Nov 2020) Favipiravir, Interferon beta- no significant differences in clinical outcome in comparison to HCQ"

(31 Aug 2020) Interferons- IFN β-1b significantly increased the discharge rate at day 14

September 2, 2020

Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial https://doi.org/10.1016/j.intimp.2020.106903 In this study (IRCT20100228003449N27), efficacy and safety of interferon (IFN) beta-1b in the treatment of patients with severe COVID-19 were evaluated. The primary outcome of the study was… Continue reading "(31 Aug 2020) Interferons- IFN β-1b significantly increased the discharge rate at day 14"

(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-β-1a and conventional therapy

June 19, 2020

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial https://www.sciencedirect.com/science/article/pii/S1567576920312893?via%3Dihub In this prospective non-controlled trial (IRCT20151227025726N12), 20 patients were included. They received IFN-β-1a at a dose of 44 µg subcutaneously every other day up to 10 days. All… Continue reading "(17 June 2020) Interferon beta1- significant recovery in 14 days with IFN-β-1a and conventional therapy"

(01 June 2020) Interferon beta- 66.7% discharge rate in IFN group on day 14 compared to 43.6% in control group

June 1, 2020

Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial https://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1 In this randomized clinical trial (Clinical Trial Registration ID #IRCT20100228003449N28)efficacy and safety of IFN β-1a has been evaluated in patients with severe COVID-19. Forty-two… Continue reading "(01 June 2020) Interferon beta- 66.7% discharge rate in IFN group on day 14 compared to 43.6% in control group"

(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance

May 25, 2020

Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study https://doi.org/10.1016/j.micinf.2020.05.012 This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged… Continue reading "(24 May 2020) Arbidol- Arbidol/IFN-α2b combination did not accelerate virus clearance"

(19 May 2020) Interferon beta- no significant impact on in-hospital survival

May 20, 2020

CLINICAL EVALUATION OF IFN BETA1B IN COVID-19 PNEUMONIA: A RETROSPECTIVE STUDY https://doi.org/10.1101/2020.05.15.20084293 In this retrospective cohort study, 256 patients (106 patients in interferon group and 150 patients in control group) were analyzed. In the interferon group, more patients received hydroxychloroquine… Continue reading "(19 May 2020) Interferon beta- no significant impact on in-hospital survival"

Tag: Interferon beta